Fiche publication
Date publication
janvier 2022
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier
,
Pr BORG Christophe
,
Dr GODET Yann
,
Dr LOYON Romain
Tous les auteurs :
Ben Khelil M, Godet Y, Abdeljaoued S, Borg C, Adotévi O, Loyon R
Lien Pubmed
Résumé
Over the past decades, CD4 T cells have been considered as a supporting actor in the fields of cancer immunotherapy. Until recently, accumulating evidence has demonstrated the critical role of CD4 T cells during antitumor immunity. CD4 T cells can either suppress or promote the antitumor cytotoxic CD8 T cell responses, either in secondary lymphoid organs or in the tumor. In this review, we provide an overview of the multifaceted role of different CD4 T cell subsets in cancer immune response and their contribution during cancer therapies. Specifically, we focus on the latest progress regarding the impact of CD4 T cell modulation on immunotherapies and other cancer therapies and discuss the prospect for harnessing CD4 T cells to control tumor progression and prevent recurrence in patients.
Mots clés
CD4+ T cells, adoptive cell transfer, cancer immunotherapy, cancer vaccine, immune checkpoint inhibitors
Référence
Cancers (Basel). 2022 Jan 5;14(1):
